Skip to main content

Decoding Depression: Mount Sinai Researchers Identify Crucial Biomarker That Tracks Recovery From Treatment-Resistant Depression


Harnessing the power of explainable AI, researchers have unveiled the first insights into the complex workings of deep-brain stimulation therapy for treatment-resistant depression.

A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression. This pattern, known as a biomarker, serves as a measurable indicator of disease recovery and represents a significant advance in treatment for the most severe and untreatable forms of depression.

The team’s findings, published online in the journal Nature on September 20, offer the first window into the intricate workings and mechanistic effects of DBS on the brain during treatment for severe depression.

Learn More

Read the Study